Targeting base excision repair suggests a new therapeutic strategy of fludarabine for the treatment of chronic lymphocytic leukemia.

Bulgar, A D; Snell, M; Donze, J R; Kirkland, E B; Li, L; Yang, S; Xu, Y; Gerson, S L; Liu, L

Bulgar, A D; Snell, M; Donze, J R; Kirkland, E B; Li, L; Yang, S; Xu, Y; Gerson, S L; Liu, L.

Leukemia ; 24(10): 1795-9, 2010 Oct.

Article in En | MEDLINE | ID: mdl-20811400

Subject(s)

Antineoplastic Agents/therapeutic use; DNA Repair/drug effects; Hydroxylamines/pharmacology; Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy; Vidarabine/analogs & derivatives; Antineoplastic Combined Chemotherapy Protocols; Apoptosis/drug effects; Blotting, Western; Cell Proliferation/drug effects; DNA (Cytosine-5-)-Methyltransferases/antagonists & inhibitors; DNA Damage/drug effects; Drug Synergism; Humans; Leukemia, Lymphocytic, Chronic, B-Cell/metabolism; Leukemia, Lymphocytic, Chronic, B-Cell/pathology; RNA, Messenger/genetics; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured; Uracil-DNA Glycosidase/metabolism; Vidarabine/therapeutic use

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Vidarabine / Leukemia, Lymphocytic, Chronic, B-Cell / DNA Repair / Hydroxylamines / Antineoplastic Agents Limits: Humans Language: En Journal: Leukemia Journal subject: HEMATOLOGIA / NEOPLASIAS Year: 2010 Document type: Article

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google